Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
出版年份 2023 全文链接
标题
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-12
出版商
Informa UK Limited
发表日期
2023-10-11
DOI
10.1080/14656566.2023.2269854
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Bexagliflozin: First Approval
- (2023) Sheridan M. Hoy DRUGS
- Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
- (2022) David M Williams et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus
- (2022) Jin Yu et al. Endocrinology and Metabolism
- The burden and risks of emerging complications of diabetes mellitus
- (2022) Dunya Tomic et al. Nature Reviews Endocrinology
- Meta-analysis Addressing the Cardiovascular Safety of Bexagliflozin in Patients With Type 2 Diabetes Mellitus
- (2022) Dimitrios Patoulias et al. AMERICAN JOURNAL OF CARDIOLOGY
- Pharmacological treatment of hyperglycemia in type 2 diabetes
- (2021) Simeon I. Taylor et al. JOURNAL OF CLINICAL INVESTIGATION
- Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
- (2021) Lauren A. Eberly et al. JAMA Network Open
- Oxidative Stress: Pathogenetic Role in Diabetes Mellitus and Its Complications and Therapeutic Approaches to Correction
- (2021) M. A. Darenskaya et al. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
- Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas
- (2021) Juan José Yepes-Nuñez et al. REVISTA ESPANOLA DE CARDIOLOGIA
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
- (2021) DIABETES CARE
- Structural basis of inhibition of the human SGLT2–MAP17 glucose transporter
- (2021) Yange Niu et al. NATURE
- Ultra-Processed Food Consumption and Adult Diabetes Risk: A Systematic Review and Dose-Response Meta-Analysis
- (2021) Sajjad Moradi et al. Nutrients
- Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease
- (2021) James Shaffner et al. Frontiers in Endocrinology
- Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
- (2020) Benedetta Maria Bonora et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Glucose transporters in the kidney in health and disease
- (2020) Volker Vallon PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
- (2020) Ryuhei Sano et al. Journal of Diabetes Investigation
- Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments
- (2020) Luke A. McGuinness et al. Research Synthesis Methods
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- 6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
- (2019) Tuba M. Ansary et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD
- (2019) Andrew S. Allegretti et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- A 96‐Week Multinational Randomized Double‐Blind Parallel‐Group Clinical Trial Evaluating the Safety and Effectiveness of Bexagliflozin as a Monotherapy for Adults with Type 2 Diabetes
- (2019) Yuan‐Di Halvorsen et al. DIABETES OBESITY & METABOLISM
- A 24‐week, randomized, double‐blind, active‐controlled clinical trial comparing bexagliflozin to sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults
- (2019) Yuan‐Di Halvorsen et al. DIABETES OBESITY & METABOLISM
- Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men
- (2019) Karin Rådholm et al. DIABETES OBESITY & METABOLISM
- Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans
- (2019) Wenbin Zhang et al. XENOBIOTICA
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- A 12‐week, randomized, double‐blind, placebo‐controlled, four‐arm dose‐finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes
- (2019) Yuan‐Di Halvorsen et al. DIABETES OBESITY & METABOLISM
- Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms
- (2018) P. C. Lee et al. Obesity Reviews
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
- (2017) Shin Kawasoe et al. BMC Pharmacology & Toxicology
- Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: A comparison of new and existing tests
- (2017) Thomas P. A. Debray et al. Research Synthesis Methods
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
- (2013) M. A. Abdul-Ghani et al. DIABETES
- EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats
- (2011) Wenbin Zhang et al. PHARMACOLOGICAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now